Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Jamshed Bomanji
Based on 4 articles published since 2010
(Why 4 articles?)

Between 2010 and 2020, Jamshed Bomanji wrote the following 4 articles about Pancreatic Neoplasms.
+ Citations + Abstracts
1 Review Role of 18F-fluorodeoxyglucose PET in the study of neuroendocrine tumors. 2014

Panagiotidis, Emmanouil / Bomanji, Jamshed. ·Institute of Nuclear Medicine, University College London Hospitals NHS Trust, London, UK. · Institute of Nuclear Medicine, University College London Hospitals NHS Trust, London, UK. Electronic address: jamshed.bomanji@uclh.nhs.uk. ·PET Clin · Pubmed #25029933.

ABSTRACT: The most widely used PET radiopharmaceutical in daily clinical practice is (18)F-fluorodeoxyglucose (FDG). The evaluation of glycolytic metabolism by (18)F-FDG is potentially useful in identifying high-risk patients with aggressive neuroendocrine disease associated with a poor outcome. Although the use of new somatostatin analogues labeled with 68-Gallium for PET has significantly increased the sensitivity of NET imaging compared with single photon emission computed tomography and (18)F-FDG-PET, (18)F-FDG may retain an important role in managing patients with NETs owing to its high prognostic value and its higher sensitivity in delineating disease extent, especially in aggressive and high-grade tumors.

2 Clinical Trial Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. 2011

Wild, Damian / Christ, Emanuel / Caplin, Martyn E / Kurzawinski, Tom R / Forrer, Flavio / Brändle, Michael / Seufert, Jochen / Weber, Wolfgang A / Bomanji, Jamshed / Perren, Aurel / Ell, Peter J / Reubi, Jean Claude. ·Institute of Nuclear Medicine, University College Hospital, London, United Kingdom. ·J Nucl Med · Pubmed #21680696.

ABSTRACT: METHODS: Eleven patients with malignant insulinoma were prospectively included. (111)In-[Lys(40)(Ahx-diethylenetriaminepentaacetic acid [DTPA])NH(2)]-exendin-4 SPECT/CT, (68)Ga- DOTATATE PET/CT, and in vitro receptor autoradiography were performed to assess the receptor status and to evaluate the detection rate. RESULTS: GLP-1 receptor targeting was positive in 4 of 11 patients, and sst(2) receptor expression was positive in 8 of 11. In only 1 patient were both receptors expressed. In 1 patient, GLP-1 receptor imaging was the only method that successfully localized the primary tumor in the pancreas. In 3 patients with sst(2)-expressing tumors, DOTATATE radiotherapy was effectively applied. CONCLUSION: As opposed to benign insulinomas, malignant insulinomas often lack GLP-1 receptors. Conversely, malignant insulinomas often express sst(2), which can be targeted therapeutically.

3 Article Use of molecular imaging to differentiate liver metastasis of colorectal cancer metastasis from neuroendocrine tumor origin. 2011

Desai, Kiran / Watkins, Jennifer / Woodward, Nicholas / Quigley, Anne Marie / Toumpanakis, Christos / Bomanji, Jamshed / Caplin, Martyn. ·Royal Free Hampstead NHS trust, UK. ·J Clin Gastroenterol · Pubmed #20861802.

ABSTRACT: Synchronous malignant neoplasms in a single patient are well documented in the literature. It is also recognized that there is increasing incidence of synchronous non-neuroendocrine neoplasm in patients with neuroendocrine tumor (NET). We present a case, of a patient with synchronous colorectal cancer and pancreatic NET, both cancers presenting with liver metastasis. By using 18F-FDG PET and 68Ga-DOTATATE PET imaging, we showed 2 different tumor types within the liver, which was subsequently confirmed on liver biopsy. This case report shows the utility of molecular imaging using different PET peptides. These newer modalities are useful in understanding the biology of the NET and in determining the best patient management.

4 Article 'Running on empty'. 2010

Wild, Damian / Theodoraki, Aikaterini / Kurzawinski, Tom R / Bomanji, Jamshed / Reubi, Jean Claude / Khan, Rehman / Bouloux, Pierre / Khoo, Bernard. ·Institute of Nuclear Medicine, University College London Hospitals NHS Trust, London, NW1 2BU, UK. ·Eur J Nucl Med Mol Imaging · Pubmed #20419372.

ABSTRACT: -- No abstract --